IDSA
@idsainfo.bsky.social
A global community of 13,000 clinicians, scientists and public health experts working together to solve humanity’s smallest and greatest challenges, from tiny microbes to global outbreaks.
Congrats to the 2025 class of Rising Leaders on completing IDSA’s online leadership development program! One of our largest cohorts yet, this group of ID and HIV practitioners strengthened leadership skills for impactful careers.
Know when 2026 applications open: idsa.tfaforms.net/f/Leadership...
Know when 2026 applications open: idsa.tfaforms.net/f/Leadership...
January 24, 2026 at 12:10 AM
Congrats to the 2025 class of Rising Leaders on completing IDSA’s online leadership development program! One of our largest cohorts yet, this group of ID and HIV practitioners strengthened leadership skills for impactful careers.
Know when 2026 applications open: idsa.tfaforms.net/f/Leadership...
Know when 2026 applications open: idsa.tfaforms.net/f/Leadership...
Land your dream job in ID and HIV, and grow your network with IDSA’s new career center!
➡️ careercenter.idsociety.org (login or account creation required)
NEW features include search based on location, specialty and setting, and job market tracking.
➡️ careercenter.idsociety.org (login or account creation required)
NEW features include search based on location, specialty and setting, and job market tracking.
January 23, 2026 at 3:28 AM
Land your dream job in ID and HIV, and grow your network with IDSA’s new career center!
➡️ careercenter.idsociety.org (login or account creation required)
NEW features include search based on location, specialty and setting, and job market tracking.
➡️ careercenter.idsociety.org (login or account creation required)
NEW features include search based on location, specialty and setting, and job market tracking.
The U.S. withdrawal from the World Health Organization is a shortsighted and misguided abandonment of our global health commitments.
Our statement: https://bit.ly/4jWGJgy
Our statement: https://bit.ly/4jWGJgy
January 22, 2026 at 4:59 PM
The U.S. withdrawal from the World Health Organization is a shortsighted and misguided abandonment of our global health commitments.
Our statement: https://bit.ly/4jWGJgy
Our statement: https://bit.ly/4jWGJgy
Today is the Day of Action. IDSA urges Congress to increase FY26 funding for medical research: https://unitedforcures.org/day-of-action
#SupportCures #FundMedicalResearch #CuresCantWait
#SupportCures #FundMedicalResearch #CuresCantWait
Day of Action — United For Cures
unitedforcures.org
January 21, 2026 at 6:30 PM
Today is the Day of Action. IDSA urges Congress to increase FY26 funding for medical research: https://unitedforcures.org/day-of-action
#SupportCures #FundMedicalResearch #CuresCantWait
#SupportCures #FundMedicalResearch #CuresCantWait
The diversity and depth of clinical research in the field of infectious diseases in 2025 were impressive, bringing new antibiotics, technologies, and solutions.
A recent CID article reviews some of the most important clinical trials and trends in ID last year: https://bit.ly/4t0iXEH
A recent CID article reviews some of the most important clinical trials and trends in ID last year: https://bit.ly/4t0iXEH
What’s Hot This Year in ID Clinical Science 2025
This review covers notable public health trends and clinical trials covering a broad range of infectious diseases topics from October 2024 to September 202
bit.ly
January 21, 2026 at 12:22 AM
The diversity and depth of clinical research in the field of infectious diseases in 2025 were impressive, bringing new antibiotics, technologies, and solutions.
A recent CID article reviews some of the most important clinical trials and trends in ID last year: https://bit.ly/4t0iXEH
A recent CID article reviews some of the most important clinical trials and trends in ID last year: https://bit.ly/4t0iXEH
IDSA CEO Jeanne Marrazzo, MD, MPH, FIDSA, shares insights on new FDA-approved gonorrhea treatments on @ashasexualhealth.bsky.social's Sex+Health podcast.
Gonorrhea is a shapeshifter! Listen to our podcast with Dr. Jeanne Marrazzo wherever you get your podcasts, and at ashasexplushealth.libsyn.com/one-two-punc... #podcast #sexplushealth #publichealth #gonorrhea #STIs
January 20, 2026 at 8:01 PM
IDSA CEO Jeanne Marrazzo, MD, MPH, FIDSA, shares insights on new FDA-approved gonorrhea treatments on @ashasexualhealth.bsky.social's Sex+Health podcast.
On IDSA’s & HIVMA’s Science Speaks blog: Kap Sum Foong, MD, FIDSA, explores how proposed legislation can help close gaps by aligning reimbursement, EHR integration and workforce training to make penicillin allergy delabeling routine across all care settings.
www.idsociety.org/science-spea...
www.idsociety.org/science-spea...
Data, policy and practice: What will it take to make penicillin allergy evaluation and delabeling routine?
Proposed legislation can help close gaps by aligning reimbursement, EHR integration and workforce training to make penicillin allergy delabeling routine across all care settings.
www.idsociety.org
January 17, 2026 at 8:53 PM
On IDSA’s & HIVMA’s Science Speaks blog: Kap Sum Foong, MD, FIDSA, explores how proposed legislation can help close gaps by aligning reimbursement, EHR integration and workforce training to make penicillin allergy delabeling routine across all care settings.
www.idsociety.org/science-spea...
www.idsociety.org/science-spea...
IDSA and other prominent medical associations are calling on courts to reverse CDC’s new recommendations for what vaccines children should get.
Read more: www.cnn.com/2026/01/14/h...
Read more: www.cnn.com/2026/01/14/h...
Medical groups will ask court to block new CDC vaccine recommendations | CNN
Six prominent medical associations say they will ask the courts to reverse the US Centers for Disease Control and Prevention’s new recommendations for what vaccines children should get.
www.cnn.com
January 15, 2026 at 7:21 PM
IDSA and other prominent medical associations are calling on courts to reverse CDC’s new recommendations for what vaccines children should get.
Read more: www.cnn.com/2026/01/14/h...
Read more: www.cnn.com/2026/01/14/h...
Post-acute sequelae of COVID-19 (long COVID) & post-acute COVID-19 vaccination syndrome present distinct challenges.
In @cidjournal.bsky.social, authors identify differences in presentation & distinguish immunologic biomarkers relevant to general clinical practice. https://bit.ly/4qRDWr0
In @cidjournal.bsky.social, authors identify differences in presentation & distinguish immunologic biomarkers relevant to general clinical practice. https://bit.ly/4qRDWr0
Overlapping Clinical Presentation of Long COVID and Postacute COVID-19 Vaccination Syndrome: Phenotypes, Severity, and Biomarkers
Postacute sequelae of COVID-19 (PASC) and postacute COVID-19 vaccination syndrome (PACVS) share significant symptom overlap, but differences in clinical pr
academic.oup.com
January 15, 2026 at 12:03 AM
Post-acute sequelae of COVID-19 (long COVID) & post-acute COVID-19 vaccination syndrome present distinct challenges.
In @cidjournal.bsky.social, authors identify differences in presentation & distinguish immunologic biomarkers relevant to general clinical practice. https://bit.ly/4qRDWr0
In @cidjournal.bsky.social, authors identify differences in presentation & distinguish immunologic biomarkers relevant to general clinical practice. https://bit.ly/4qRDWr0
Thanks to the incredible support of the ID community, the IDSA Foundation successfully met our Dec. 2025 matching gift challenge! Thank you to those that supported our work in 2025 and we look forward to building on this momentum in 2026.
Learn more: https://www.idsafoundation.org/our-impact
Learn more: https://www.idsafoundation.org/our-impact
January 14, 2026 at 9:15 PM
Thanks to the incredible support of the ID community, the IDSA Foundation successfully met our Dec. 2025 matching gift challenge! Thank you to those that supported our work in 2025 and we look forward to building on this momentum in 2026.
Learn more: https://www.idsafoundation.org/our-impact
Learn more: https://www.idsafoundation.org/our-impact
Learn the latest on travel-associated histoplasmosis during a CDC COCA Call this Thurs. Jan. 15 from 2-3pm ET.
Register: https://bit.ly/4jApqBA
Register: https://bit.ly/4jApqBA
From Cave to Clinic: Managing Histoplasmosis in Returning Travelers
COCA Call: evidence on travel histoplasmosis, focusing on cave outbreaks in Central/South America
bit.ly
January 13, 2026 at 5:56 PM
Learn the latest on travel-associated histoplasmosis during a CDC COCA Call this Thurs. Jan. 15 from 2-3pm ET.
Register: https://bit.ly/4jApqBA
Register: https://bit.ly/4jApqBA
Missed last month’s IDSA Fellows Case Conference? A recording is now available on the IDSA Academy!
Explore a complex ID case, hear expert insights, and learn alongside your peers: https://bit.ly/4sBU9m3
Explore a complex ID case, hear expert insights, and learn alongside your peers: https://bit.ly/4sBU9m3
January 12, 2026 at 6:49 PM
Missed last month’s IDSA Fellows Case Conference? A recording is now available on the IDSA Academy!
Explore a complex ID case, hear expert insights, and learn alongside your peers: https://bit.ly/4sBU9m3
Explore a complex ID case, hear expert insights, and learn alongside your peers: https://bit.ly/4sBU9m3
Candidemia is a life-threatening infection with high mortality, and in-depth analyses of Candida Care Bundle compliance remain limited. In OFID, authors investigated the impact of bundle compliance on survival among patients with candidemia. https://academic.oup.com/ofid/article/13/1/ofaf790/8403191
Impact of Candida Care Bundle Compliance on the Prognosis of Patients With Candidemia: A Multicenter Retrospective Cohort Study With Propensity Score Matching Analysis (2016–2023)
AbstractBackground. Candidemia is a life-threatening infection with high mortality, and appropriate management is essential to improve patient outcomes. Th
academic.oup.com
January 10, 2026 at 7:21 PM
Candidemia is a life-threatening infection with high mortality, and in-depth analyses of Candida Care Bundle compliance remain limited. In OFID, authors investigated the impact of bundle compliance on survival among patients with candidemia. https://academic.oup.com/ofid/article/13/1/ofaf790/8403191
We urge Congress to investigate why the schedule was changed and why credible scientific evidence was ignored.
Read the full sign-on letter: www.idsociety.org/news--public...
Read the full sign-on letter: www.idsociety.org/news--public...
January 9, 2026 at 11:17 PM
We urge Congress to investigate why the schedule was changed and why credible scientific evidence was ignored.
Read the full sign-on letter: www.idsociety.org/news--public...
Read the full sign-on letter: www.idsociety.org/news--public...
The second installment of the ID Clinical Bootcamp for APPs, with new content from the #IDWeek2025 premeeting workshop, is available as an accredited course on the IDSA Academy!
Register by Feb. 28 with the code APPBOOTCAMP to claim a 10% discount: https://bit.ly/3Nh09jR
Register by Feb. 28 with the code APPBOOTCAMP to claim a 10% discount: https://bit.ly/3Nh09jR
January 8, 2026 at 8:50 PM
The second installment of the ID Clinical Bootcamp for APPs, with new content from the #IDWeek2025 premeeting workshop, is available as an accredited course on the IDSA Academy!
Register by Feb. 28 with the code APPBOOTCAMP to claim a 10% discount: https://bit.ly/3Nh09jR
Register by Feb. 28 with the code APPBOOTCAMP to claim a 10% discount: https://bit.ly/3Nh09jR
On IDSA’s & HIVMA’s Science Speaks blog: Melvin Sanicas, MD, MSc, MScID, MBA, explores what’s on the horizon for vaccines for tick-borne diseases and shares clinical takeaways for 2026. www.idsociety.org/science-spea...
Tick-borne disease vaccines: What clinicians should know in 2026
www.idsociety.org
January 7, 2026 at 5:56 PM
On IDSA’s & HIVMA’s Science Speaks blog: Melvin Sanicas, MD, MSc, MScID, MBA, explores what’s on the horizon for vaccines for tick-borne diseases and shares clinical takeaways for 2026. www.idsociety.org/science-spea...
In CID, authors evaluated the distribution of #HIV drug resistance mutations (DRMs) before treatment randomization in individuals failing first-line therapy in the D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) trial. https://bit.ly/3Ln8HFe
Regional variations of rates and determinants of drug resistance mutations in people failing first-line therapy for HIV-1: a substudy from the D2EFT phase 3b/4 clinical trial
academic.oup.com
January 6, 2026 at 9:06 PM
In CID, authors evaluated the distribution of #HIV drug resistance mutations (DRMs) before treatment randomization in individuals failing first-line therapy in the D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) trial. https://bit.ly/3Ln8HFe
Today’s announcement that HHS is drastically altering the U.S. childhood vaccine schedule without a transparent process or clear scientific justification represents the latest reckless step in Secretary Kennedy’s assault on the national vaccine infrastructure.
Our statement: https://bit.ly/497Tj8V
Our statement: https://bit.ly/497Tj8V
January 5, 2026 at 10:37 PM
Today’s announcement that HHS is drastically altering the U.S. childhood vaccine schedule without a transparent process or clear scientific justification represents the latest reckless step in Secretary Kennedy’s assault on the national vaccine infrastructure.
Our statement: https://bit.ly/497Tj8V
Our statement: https://bit.ly/497Tj8V
In CID, authors investigated the prevalence of N. farcinica infection in a pathologically confirmed Kikuchi-Fujimoto disease (KFD) cohort to analyze its correlation with clinical phenotypes in comparison to Castleman disease (CD). https://bit.ly/4snLfIK
Nocardia farcinica as a potential pathogen associated with a clinical subtype of Kikuchi-Fujimoto disease
Nocardia farcinica is potentially linked to Kikuchi-Fujimoto disease, characterizing a clinical subtype characterized by older age, rapid symptom onset, an
academic.oup.com
January 3, 2026 at 7:20 PM
In CID, authors investigated the prevalence of N. farcinica infection in a pathologically confirmed Kikuchi-Fujimoto disease (KFD) cohort to analyze its correlation with clinical phenotypes in comparison to Castleman disease (CD). https://bit.ly/4snLfIK
As we step into 2026, we carry forward both the accomplishments of 2025 and the spirit behind them: a willingness to act with courage, to lead with science and to stand firmly with patients and colleagues through these uncertain times.
Take a look at our 2025 Year in Review: https://bit.ly/49zfTr9
Take a look at our 2025 Year in Review: https://bit.ly/49zfTr9
December 31, 2025 at 6:15 PM
As we step into 2026, we carry forward both the accomplishments of 2025 and the spirit behind them: a willingness to act with courage, to lead with science and to stand firmly with patients and colleagues through these uncertain times.
Take a look at our 2025 Year in Review: https://bit.ly/49zfTr9
Take a look at our 2025 Year in Review: https://bit.ly/49zfTr9
TODAY is the final day to double your impact! ⏰ Don’t miss your chance to make twice the difference by contributing to the IDSA Foundation matching gift challenge: givetothe.idsafoundation.org/campaign/748...
December 31, 2025 at 4:06 PM
TODAY is the final day to double your impact! ⏰ Don’t miss your chance to make twice the difference by contributing to the IDSA Foundation matching gift challenge: givetothe.idsafoundation.org/campaign/748...
🚨Deadline approaching! Do you have all the credits you need? Earn points through the IDSA Academy by TOMORROW, Dec. 31 to maintain your certification status: https://academy.idsociety.org/
December 30, 2025 at 9:45 PM
🚨Deadline approaching! Do you have all the credits you need? Earn points through the IDSA Academy by TOMORROW, Dec. 31 to maintain your certification status: https://academy.idsociety.org/
Extensive literature has established equivalent efficacy of early intravenous (IV) to oral antibiotic transition. In CID, authors determined impact of early oral transition in a real-world setting and studied its influence on practice transformation. https://bit.ly/4pkEAMT
Using the Comparing Oral versus Parenteral Antimicrobial Therapy (COPAT) Clinical Trial to Influence Institutional Practice Transformation Towards Earlier Transition to Oral Antibiotics
Early IV to oral transition improves antibiotic treatment safety across many serious infections. In a rural health system, implementation of the COPAT Tria
academic.oup.com
December 30, 2025 at 5:51 PM
Extensive literature has established equivalent efficacy of early intravenous (IV) to oral antibiotic transition. In CID, authors determined impact of early oral transition in a real-world setting and studied its influence on practice transformation. https://bit.ly/4pkEAMT
Advancing the future of infectious diseases starts with your support. Through Dec. 31, gifts are matched dollar-for-dollar until we reach our goal of $100,000, helping fuel mentorship, research and education for the next generation of ID experts.
Donate today: https://bit.ly/3KuTRvX
Donate today: https://bit.ly/3KuTRvX
December 30, 2025 at 12:19 AM
Advancing the future of infectious diseases starts with your support. Through Dec. 31, gifts are matched dollar-for-dollar until we reach our goal of $100,000, helping fuel mentorship, research and education for the next generation of ID experts.
Donate today: https://bit.ly/3KuTRvX
Donate today: https://bit.ly/3KuTRvX
On IDSA’s & HIVMA’s Science Speaks blog: Read JID’s latest monthly roundup of papers relevant to clinicians, including articles on factors that increase RSV hospitalization risk, how differences in baseline median ANC can impact clinical management and more. https://bit.ly/49cze06
JID for Clinicians: Using CPS-Ped to measure RSV in infants, immunologic markers of chronic Chagas disease and more
Learn about how vaccination can prevent herpes zoster, underlying mechanisms that may contribute to an increased risk of HIV in association with bacterial vaginosis and other research ready to inform clinical practice.
www.idsociety.org
December 28, 2025 at 6:23 PM
On IDSA’s & HIVMA’s Science Speaks blog: Read JID’s latest monthly roundup of papers relevant to clinicians, including articles on factors that increase RSV hospitalization risk, how differences in baseline median ANC can impact clinical management and more. https://bit.ly/49cze06